Overview

Detailed Summary

Blue Jet Healthcare is a Mumbai‑headquartered specialty pharmaceutical and CDMO company manufacturing contrast media intermediates, high‑intensity sweeteners (saccharin and salts) and pharma intermediates/APIs, operating multiple regulatory‑accredited facilities and providing development, process research, and contract manufacturing solutions to global innovators and generic players.
Q3 FY26 reported revenue of Rs.1,924 mn with EBITDA of Rs.469 mn (24% margin) and PAT of Rs.402 mn, while 9M FY26 revenue is Rs.7,127 mn with EBITDA margin of 31% and PAT margin of 26%; recent quarter saw sharp YoY decline driven by customer de‑stocking and product mix shifts but nine‑month performance remains resilient.
Company is executing a large, multi‑year capex agenda including a board‑approved Rs.1,000 crore Vizag greenfield project, near‑completion of a Mahad backward‑integration block and an expanded R&D lease in Hyderabad, signalling strategic vertical integration and CDMO pipeline enablement that materially alters scale and capability for Blue Jet Healthcare.
Blue Jet’s competitive edge rests on complex chemistry capabilities, ~70% contracted sales, long tenures with top contrast media manufacturers, regulatory accreditations and targeted forward integration into advanced intermediates, providing Blue Jet Healthcare with sticky client relationships and differentiated margin potential in high barrier segments.
Operational and margin volatility in recent quarters has been influenced by customer de‑stocking, one‑time inventory write‑offs and engagement of foreign consultants; management expects normalization over a couple of quarters while pursuing sustainability targets (70% renewables) and award recognition for energy management at Blue Jet Healthcare.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 7,210 Cr
Volatility: High Risk
P/E Ratio: 0.3
Industry P/E: 32.2
PEG Ratio: —
P/B Ratio: 5.7
52W High: 1,028.20
52W Low: 325.20

Sales CAGR

1Y: -7.30%
3Y: 14.65%
5Y: 13.86%
10Y: —

Profit CAGR

1Y: -6.33%
3Y: 18.90%
5Y: 16.10%
10Y: —

ROE

TTM: 28.06%
3Y: 23.65%
5Y: 27.04%
10Y: —

ROCE

TTM: 37.35%
3Y: 31.24%
5Y: 35.60%
10Y: —

Technicals

‌

Forecasts

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
JSLL		654.95	8,403 Cr	26.37	23.76	0.16	42.02	46.06	36.87
SANOFI		3380.10	8,112 Cr	19.65	9.43	3.49	42.11	52.41	25.64
MARKSANS		176.15	8,016 Cr	22.13	2.98	0.45	13.08	16.13	10.51
SHILPAMED		420.00	7,919 Cr	50.94	3.25	0.12	6.35	8.41	4.29
SUDEEPPHRM		603.60	7,387 Cr	47.19	9.00	0.00	20.63	23.80	17.20
BLUEJET		362.30	7,210 Cr	0.26	5.74	0.29	28.06	37.35	19.22
AARTIPHARM		701.00	6,405 Cr	29.75	3.13	0.71	11.72	12.99	6.54
Median: 7 Co.	—	603.60	7,919 Cr	26.37	5.74	0.29	20.63	23.80	17.20

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	181	167	184	163	208	318	340	355	165	192
Expenses	119	112	131	119	139	194	200	234	111	146
Operating Profit	63	55	53	44	69	124	140	121	55	47
OPM %	34.53	32.74	28.85	27.17	33.37	38.95	41.12	34.11	33.21	24.36
Other Income	8.21	-2.99	8.83	8.72	12	13	12	8.25	24	13
Interest	0.04	0.04	0.03	0.03	0.02	0.02	0.03	0.69	4.63	0.34
Depreciation	6.47	7.86	7.72	3.48	4.62	4.75	4.95	5.70	5.87	5.98
Profit Before Tax	64	44	54	49	77	132	147	123	69	54
Tax %	25.59	26.52	26.78	23.63	24.15	25.29	25.22	25.79	24.14	25.31
Net Profit	48	32	40	38	58	99	110	91	52	40
EPS in Rs	—	1.85	2.29	2.18	3.36	5.71	6.35	5.26	3.01	2.32

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021
Sales	538	499
Expenses	324	293
Operating Profit	214	206
OPM %	39.71	41.26
Other Income	5.81	3.75
Interest	7.37	5.31
Depreciation	18	20
Profit Before Tax	194	185
Tax %	25.33	26.47
Net Profit	145	136
EPS in Rs	—	—
Dividend Payout %	0.00	0.00

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021
Equity Capital	0.60	9.91
Reserves	201	330
Borrowings	78	52
Other Liabilities	96	145
Total Liabilities	375	536
Fixed Assets	107	139
CWIP	2.04	2.58
Investments	34	37
Other Assets	233	358
Total Assets	375	536

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021
Cash from Operating Activity	123	129
Cash from Investing Activity	-45	-51
Cash from Financing Activity	-72	-27
Net Cash Flow	5.00	51

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Sep 2022	Oct 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	100.00%	86.00%	86.00%	86.00%	86.00%	86.00%	86.00%	86.00%	86.00%	79.81%	79.81%	79.81%
FIIs	0.00%	2.72%	2.93%	2.01%	2.02%	2.18%	1.10%	2.29%	1.97%	1.82%	1.14%	0.88%
DIIs	0.00%	4.28%	3.70%	3.03%	2.14%	1.74%	2.02%	1.33%	0.94%	3.63%	4.65%	4.51%
Public	0.00%	7.00%	7.37%	8.96%	9.83%	10.07%	10.87%	10.38%	11.09%	14.74%	14.41%	14.80%
Total Shareholders	7	2,03,777	55,589	48,625	42,882	41,933	43,003	54,581	70,772	80,117	80,187	79,199

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Available on Pro Plan